FIELD: biotechnology; medicine.
SUBSTANCE: set is intended for quality control of determination of five main diagnostically significant genetic mutations: JAK2V617F, MPLW515K and MPLW515L, CALR of 1st and 2nd types.
EFFECT: what is presented is a method for preparing a set of standard samples for quality control of molecular genetic diagnosis of Ph-negative myeloproliferative diseases.
1 cl, 1 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SET OF REACTIVES FOR IDENTIFICATION OF Ph-NEGATIVE MYELOPROLIFERATIVE BLASTOMA AND A METHOD OF DIAGNOSTICS BASED ON IT | 2018 |
|
RU2679653C1 |
| SET OF REAGENTS FOR SIMULTANEOUS DETECTION OF FIVE MAJOR SOMATIC MUTATIONS IN pH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS AND DIAGNOSTIC METHOD BASED ON IT | 2022 |
|
RU2802421C1 |
| METHOD FOR DETERMINING MUTATIONS IN THE CALR GENE BY ANALYZING MELTING CURVES IN THE PATIENTS SUFFERING CHRONIC MYELOPROLIFERATIVE DISEASES | 2019 |
|
RU2722077C1 |
| METHOD FOR DETERMINING A RISK OF DEVELOPING A CEREBROVASCULAR PATHOLOGY IN MYELOPROLIFERATIVE DISEASES | 2020 |
|
RU2727005C1 |
| METHOD OF DIFFERENTIAL DIAGNOSTICS OF HEADACHE TYPE IN CASE OF MYELOPROLIFERATIVE DISEASES | 2016 |
|
RU2609287C1 |
| METHOD OF COMBINATORIAL THERAPY IN TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS WITH HUMAN INTERLEUKIN-3 DIPHTHERIA TOXIN CONJUGATE IN COMBINATION WITH OTHER AGENTS | 2019 |
|
RU2837724C2 |
| METHOD FOR PREDICTION OF ACUTE VASCULAR EVENTS IN PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS BASED ON LEVEL OF BONE MARROW EXPRESSION OF MMP9 | 2023 |
|
RU2819657C1 |
| MUTANT CALRETICULIN FOR DIAGNOSIS OF MYELOID MALIGNANCIES | 2014 |
|
RU2668808C2 |
| SET OF REAGENTS FOR THE DETECTION OF PATHOGENS OF TICK-BORNE BORRELIOSIS | 2021 |
|
RU2763595C1 |
| COMPOSITIONS AND METHODS FOR MYELOFIBROSIS TREATMENT | 2011 |
|
RU2616262C2 |
